Accessibility Menu
 
ProKidney logo

ProKidney

(NASDAQ) PROK

Current Price$1.59
Market Cap$227.11M
Since IPO (2021)-84%
5 YearN/A
1 Year+70%
1 Month-29%

ProKidney Financials at a Glance

Market Cap

$227.11M

Revenue (TTM)

$893.00K

Net Income (TTM)

$68.99M

EPS (TTM)

$-0.52

P/E Ratio

-3.10

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.59

Volume

45,047

Open

$1.71

Previous Close

$1.59

Daily Range

$1.58 - $1.71

52-Week Range

$0.46 - $7.13

PROK: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProKidney

Industry

Biotechnology

Employees

231

CEO

Bruce Culleton, MD, MBA

Headquarters

Winston-Salem, NC 27103, US

PROK Financials

Key Financial Metrics (TTM)

Gross Margin

-2%

Operating Margin

-185%

Net Income Margin

-77%

Return on Equity

0%

Return on Capital

-54%

Return on Assets

-21%

Earnings Yield

-32.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$227.11M

Shares Outstanding

141.94M

Volume

45.05K

Short Interest

0.00%

Avg. Volume

871.26K

Financials (TTM)

Gross Profit

$4.83M

Operating Income

$165.01M

EBITDA

$158.97M

Operating Cash Flow

$120.12M

Capital Expenditure

$15.20M

Free Cash Flow

$135.31M

Cash & ST Invst.

$270.02M

Total Debt

$2.96M

ProKidney Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$225.00K

+196.1%

Gross Profit

$1.22M

-1710.5%

Gross Margin

-5.44%

N/A

Market Cap

$227.11M

N/A

Market Cap/Employee

$1.11M

N/A

Employees

204

N/A

Net Income

$19.23M

+9.6%

EBITDA

$43.92M

+2.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$267.05M

-24.8%

Accounts Receivable

$1.13M

-53.9%

Inventory

$0.00

N/A

Long Term Debt

$2.96M

+20.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-20.56%

N/A

Return on Invested Capital

-54.13%

N/A

Free Cash Flow

$38.27M

+23.0%

Operating Cash Flow

$32.51M

-34.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RZLTRezolute, Inc.
$2.99-8.00%
PRMEPrime Medicine, Inc.
$3.38-7.14%
KURAKura Oncology, Inc.
$7.74-7.42%
BCAXBicara Therapeutics Inc. Common Stock
$18.37-2.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About PROK

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.